Literature DB >> 16429254

Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis.

T Neumann1, P Oelzner, P K Petrow, K Thoss, G Hein, G Stein, R Bräuer.   

Abstract

OBJECTIVE: To assess the effect of osteoprotegerin (OPG) on joint swelling, synovial inflammation and cartilage destruction, periarticular and axial bone volume, and bone turnover in rat antigen-induced arthritis (AIA).
DESIGN: Rats were treated with OPG (3 mg/kg/day) at regular intervals from day 1 to day 20 of AIA. Disease activity was evaluated by measurement of joint swelling as well as, joint inflammation and destruction by histology. Bone volume and cellular turnover parameters of secondary spongiosa of the right tibia head and the third lumbar vertebra were evaluated by histomorphometry. Periarticular bone volume of the primary spongiosa at the right tibia head was measured by linear scanning. The findings were compared with those of PBS-treated AIA and healthy animals. RESULT: OPG treatment did not reduce joint swelling or histological signs of inflammation. Cartilage destruction was reduced. However, this effect did not reach statistical significance . In the secondary spongiosa OPG treatment reduced the loss of periarticular bone volume. However, the latter did not reach the level of healthy controls. OPG treatment significantly reduced parameters of bone formation and bone resorption. In the primary spongiosa, OPG-treatment led to a higher amount of mineralized tissue and a greater number of trabeculae compared to PBS-treated animals with AIA or healthy controls. In the axial skeleton, OPG treatment reduced bone formation and bone resorption parameters compared to healthy animals. This treatment had no influence on bone volume.
CONCLUSIONS: In periarticular bone of AIA rats, OPG treatment reduced the loss of bone volume and decreased the bone turnover, thus preventing periarticular bone destruction. OPG treatment had no influence on inflammatory process or on cartilage destruction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16429254     DOI: 10.1007/s00011-005-0005-5

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  7 in total

1.  Combination therapy with dexamethasone and osteoprotegerin protects against arthritis-induced bone alterations in antigen-induced arthritis of the rat.

Authors:  P Oelzner; S Fleissner-Richter; R Bräuer; G Hein; G Wolf; T Neumann
Journal:  Inflamm Res       Date:  2010-03-20       Impact factor: 4.575

Review 2.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

3.  1,25-Dihydroxyvitamin D3 prevents bone loss of the secondary spongiosa in arthritic rats by an increase of bone formation and mineralization and inhibition of bone resorption.

Authors:  Peter Oelzner; Peter K Petrow; Gunter Wolf; Rolf Bräuer
Journal:  BMC Musculoskelet Disord       Date:  2014-10-14       Impact factor: 2.362

4.  RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.

Authors:  Marina Stolina; Georg Schett; Denise Dwyer; Steven Vonderfecht; Scot Middleton; Diane Duryea; Efrain Pacheco; Gwyneth Van; Brad Bolon; Ulrich Feige; Debra Zack; Paul Kostenuik
Journal:  Arthritis Res Ther       Date:  2009-12-11       Impact factor: 5.156

5.  Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: a microCT study.

Authors:  Massimo Marenzana; Alex Vugler; Adrian Moore; Martyn Robinson
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

6.  Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients.

Authors:  Jun Xie; Shaohua Li; Lianbo Xiao; Guilin Ouyang; Lin Zheng; Yubiao Gu; Chengxin Gao; Xiuwei Han
Journal:  J Orthop Surg Res       Date:  2019-12-10       Impact factor: 2.359

7.  Osteoprotegerin Prevents Intracranial Aneurysm Progression by Promoting Collagen Biosynthesis and Vascular Smooth Muscle Cell Proliferation.

Authors:  Takeshi Miyata; Manabu Minami; Hiroharu Kataoka; Kosuke Hayashi; Taichi Ikedo; Tao Yang; Yu Yamamoto; Masayuki Yokode; Susumu Miyamoto
Journal:  J Am Heart Assoc       Date:  2020-08-28       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.